A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 plus bevacizumab (IRIS+BV) and modified FOLFIRI plus BV (mFOLFIRI+BV) in patients (pts) with metastatic colorectal cancer (mCRC): The result of efficacy report of T-CORE0702.
H. Andoh
No relevant relationships to disclose
S. Kato
No relevant relationships to disclose
M. Gamoh
No relevant relationships to disclose
T. Yamaguchi
No relevant relationships to disclose
M. Sakayori
No relevant relationships to disclose
Y. Sasaki
No relevant relationships to disclose
T. Mori
No relevant relationships to disclose
H. Ohori
No relevant relationships to disclose
T. Yoshioka
No relevant relationships to disclose
C. Ishioka
Research Funding - Chugai Pharma; Taiho Pharmaceutical